These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36971576)

  • 41. Pharmacological Profile of Naldemedine, a Peripherally Acting
    Kanemasa T; Koike K; Takase K; Arai T; Nakamura A; Morioka Y; Hasegawa M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):438-444. PubMed ID: 32169839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Naldemedine for opioid-induced constipation.
    Drug Ther Bull; 2022 Mar; 60(3):39-43. PubMed ID: 35197302
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis.
    Ouyang R; Li Z; Huang S; Liu J; Huang J
    Pain Med; 2020 Nov; 21(11):3224-3232. PubMed ID: 32488259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
    Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
    Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics.
    Nakatsugawa E; Naito T; Shibata K; Kitajima R; Kawakami J
    Fundam Clin Pharmacol; 2024 Jun; 38(3):596-605. PubMed ID: 38192190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
    Kanemasa T; Koike K; Arai T; Ono H; Horita N; Chiba H; Nakamura A; Morioka Y; Kihara T; Hasegawa M
    Neurogastroenterol Motil; 2019 May; 31(5):e13563. PubMed ID: 30821019
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting.
    Sato R; Ishida M; Uchida N; Sakimoto T; Yamaguchi T; Ooya Y; Takahashi T; Onishi H
    Palliat Support Care; 2023 Oct; 21(5):957-959. PubMed ID: 37350233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis.
    Ishida M; Hiraoka M; Yaguchi A; Sugano K; Adachi N; Itoga T; Ishiguro T; Onishi H
    Palliat Support Care; 2022 Jun; 20(3):445-447. PubMed ID: 34955117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study.
    Mori M; Ji Y; Kumar S; Ashikaga T; Ades S
    Int J Clin Oncol; 2017 Apr; 22(2):397-404. PubMed ID: 27628064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preventive effects of naldemedine, peripherally acting μ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
    Kanemasa T; Matsuzaki T; Koike K; Hasegawa M; Suzuki T
    Life Sci; 2020 Sep; 257():118048. PubMed ID: 32622946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children.
    Miura R; Utano T; Miura Y; Chiba K; Hasegawa A; Takafuji Y; Takahashi H; Tanzawa A; Iwahashi K; Yamatani A; Yotani N
    J Palliat Med; 2024 Aug; ():. PubMed ID: 39122251
    [No Abstract]   [Full Text] [Related]  

  • 53. Methylnaltrexone: treatment for opioid-induced constipation.
    Licup N; Baumrucker SJ
    Am J Hosp Palliat Care; 2011 Feb; 28(1):59-61. PubMed ID: 20801917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A New Twist on the Administration of Naldemedine for Opioid-Induced Constipation in an Outpatient].
    Shikada Y; Emi Y; Kometani T; Ochiai T; Fujii M; Noda Y; Kajiwara M; Ikeda M; Asonuma S; Mori M
    Gan To Kagaku Ryoho; 2018 Jul; 45(7):1075-1079. PubMed ID: 30042276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.
    Murphy JA; Sheridan EA
    Ann Pharmacother; 2018 Apr; 52(4):370-379. PubMed ID: 29092627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial.
    Webster LR; Michna E; Khan A; Israel RJ; Harper JR
    Pain Med; 2017 Aug; 18(8):1496-1504. PubMed ID: 28810695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
    Ozaki A; Kessoku T; Iwaki M; Kobayashi T; Yoshihara T; Kato T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Yoneda M; Taguri M; Yamanaka T; Ishiki H; Kobayashi N; Saito S; Ichikawa Y; Nakajima A
    Trials; 2020 Jun; 21(1):453. PubMed ID: 32487150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy.
    Webster LR; Hale ME; Yamada T; Wild JE
    J Pain Res; 2020; 13():605-612. PubMed ID: 32280263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
    Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety.
    Pergolizzi JV; Christo PJ; LeQuang JA; Magnusson P
    Drug Des Devel Ther; 2020; 14():1009-1025. PubMed ID: 32210534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.